Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Signos Inc
The scope of this study is to enroll existing and new Signos non-insulin dependent type 2 diabetes mellitus users in a volunteer study that utilizes a continuous glucose monitor (CGM) and mobile health application \[Signos\] to optimize general wellness and body weight and composition. This is a no more than minimal risk study.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Medical diagnosis of Type 2 Diabetes; determined by review of subject-provided most recent Hg A1c.
Subject is under current care of a primary care provider or specialist
Clearance by medical provider to participate in diet, physical activity, and lifestyle changes
18 years and above
Own a smartphone and be willing to install the Signos App to personally receive text messages or have access to a web-based survey to self-report their weight.
Willingness to complete quality of life questionnaires or other in-app surveys.
Willingness to use CGM device
Able to speak and read English
Be a Signos mHealth (mobile/web-based) user
You may not be if
Medical diagnosis of Type 1 Diabetes
Type 2 Diabetes currently using insulin or most recent A1c ≥10%
Severe hypoglycemia \<54 mg/dl resulting in seizure or unconsciousness, or requiring assistance/EMS/hospitalization - within 3 months prior to enrollment
Current medical diagnosis of an eating disorder (such as anorexia nervosa or bulimia)
Medical conditions (e.g., such as seizure disorder) requiring a specific medical diet.
Inborn error of metabolism such as phenylketonuria (PKU), glycogen storage disease, fructose intolerance, Maple Sugar Urine Disease (MSUD).
History of 10 or more soft tissue skin infections (such as cellulitis or abscesses)
Intolerable skin reaction from adhesive
Currently taking any of the following medications: Clozapine, Hydroxyurea, or any form of insulin.
Clareo Health | Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
